David C Montefiori
Overview
Explore the profile of David C Montefiori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
605
Citations
36312
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Walsh S, Gay C, Karuna S, Hyrien O, Skalland T, Mayer K, et al.
PLoS Med
. 2024 Jun;
21(6):e1004329.
PMID: 38913710
Background: Broadly neutralizing antibodies (bnAbs) are a promising approach for HIV-1 prevention. In the Antibody Mediated Prevention (AMP) trials, a CD4-binding site targeting bnAb, VRC01, administered intravenously (IV), demonstrated 75%...
12.
Wu C, Raheem I, Nahas D, Citron M, Kim P, Montefiori D, et al.
Proc Natl Acad Sci U S A
. 2024 May;
121(22):e2317230121.
PMID: 38768344
Efforts to develop an HIV-1 vaccine include those focusing on conserved structural elements as the target of broadly neutralizing monoclonal antibodies. MAb D5 binds to a highly conserved hydrophobic pocket...
13.
Hahn W, Parks K, Shen M, Ozorowski G, Janes H, Ballweber-Fleming L, et al.
medRxiv
. 2024 May;
PMID: 38766048
Key Takeaway/take-home Messages: HIV BG505 SOSIP.664 trimer with novel 3M-052-AF/alum adjuvant in humans appears safe and induces serum neutralizing antibodies to matched clade A, tier 2 virus, that map to...
14.
Ober Shepherd B, Scott P, Hutter J, Lee C, McCauley M, Guzman I, et al.
Lancet Microbe
. 2024 May;
5(6):e581-e593.
PMID: 38761816
Background: A self-assembling SARS-CoV-2 WA-1 recombinant spike ferritin nanoparticle (SpFN) vaccine co-formulated with Army Liposomal Formulation (ALFQ) adjuvant containing monophosphoryl lipid A and QS-21 (SpFN/ALFQ) has shown protective efficacy in...
15.
Williams W, Alam S, Ofek G, Erdmann N, Montefiori D, Seaman M, et al.
Cell
. 2024 May;
187(12):2919-2934.e20.
PMID: 38761800
A critical roadblock to HIV vaccine development is the inability to induce B cell lineages of broadly neutralizing antibodies (bnAbs) in humans. In people living with HIV-1, bnAbs take years...
16.
Muhlemann B, Wilks S, Baracco L, Bekliz M, Carreno J, Corman V, et al.
Sci Transl Med
. 2024 May;
16(747):eadl1722.
PMID: 38748773
The evolution of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires ongoing monitoring to judge the ability of newly arising variants to escape the immune response. A surveillance system necessitates...
17.
Frank I, Li S, Grunenberg N, Overton E, Robinson S, Zheng H, et al.
Lancet HIV
. 2024 May;
11(5):e285-e299.
PMID: 38692824
Background: An effective HIV vaccine will most likely need to have potent immunogenicity and broad cross-subtype coverage. The aim of the HIV Vaccine Trials Network (HVTN) 124 was to evaluate...
18.
Wiehe K, Saunders K, Stalls V, Cain D, Venkatayogi S, Martin Beem J, et al.
Cell Host Microbe
. 2024 Apr;
32(5):693-709.e7.
PMID: 38670093
A major goal of HIV-1 vaccine development is the induction of broadly neutralizing antibodies (bnAbs). Although success has been achieved in initiating bnAb B cell lineages, design of boosting immunogens...
19.
Erdmann N, Williams W, Walsh S, Grunenberg N, Edlefsen P, Goepfert P, et al.
medRxiv
. 2024 Apr;
PMID: 38562833
Background: HIV-1 vaccine development is a global health priority. Broadly neutralizing antibodies (bnAbs) which target the HIV-1 gp41 membrane-proximal external region (MPER) have some of the highest neutralization breadth. An...
20.
Reeves D, Mayer B, deCamp A, Huang Y, Zhang B, Carpp L, et al.
Nat Commun
. 2024 Mar;
15(1):2575.
PMID: 38519455
No abstract available.